Buy & Sell Gilead Sciences, Inc. (GILD) – Gilead Sciences, Inc. Price Today
Aura AI Summary
Key Stats
- $166.90BMarket Cap
- HealthSector
- -14.85%3M Drawdown
- $181.44BEnterprise Value
- 2.44%Dividend Yield
- 94 daysTypical Hold Time
Gilead Sciences, Inc. (GILD) is currently valued at a market capitalization of $166.90B, with an enterprise value of $181.44B. Over the past 52 weeks, Gilead Sciences, Inc. has traded between a low of $105.93 and a high of $155.8, highlighting its annual price range. Over the past three months, Gilead Sciences, Inc. has recorded a drawdown of -14.85%, reflecting recent price volatility. Gilead Sciences, Inc. offers a dividend yield of 2.44%, with the most recent dividend of $0.82 paid on 13 Mar 26. On average, investors hold Gilead Sciences, Inc. for approximately 94 days, indicating typical investor behavior on the platform.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Most Recent News
Stock and oil futures open as Iran war enters fourth month with no resolution.
Stock and oil futures began trading as the conflict in Iran entered its fourth month without any signs of resolution. The ongoing war continues to influence market sentiment and commodity prices, keeping investors cautious. Traders will be watching f...

CAPHRA urges full stakeholder inclusion in Asia Pacific tobacco control policies for better public health outcomes.
The Coalition of Asia Pacific Harm Reduction Advocates (CAPHRA) released a position paper calling for formal inclusion of all key stakeholders in tobacco control policy-making across the Asia Pacific. They argue that policies made without meaningful ...

Diana Shipping pushes to replace Genco's board with six independent nominees amid takeover bid.
Diana Shipping, the largest shareholder of Genco Shipping & Trading, has sent an open letter urging Genco shareholders to elect six independent director nominees at the upcoming annual meeting. Diana criticizes the current Genco board for prioritizin...
